Drug Formulary Review Archives – September 1, 2005
September 1, 2005
View Issues
-
Joint Commission issues alert on vincristine administration
Saying tragic errors related to vincristine administration continue to occur, the Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL, issued a Sentinel Event Alert in July. -
New law legally protects adverse event information
Pharmacists should be encouraged to report medication adverse events (AEs) and their underlying causes under a new law signed by President Bush on July 29. -
Study: Number of adverse events involves med errors
A teaching hospital further improved its existing safety mechanisms after a study of critically ill patients found a significant number of adverse events involving medications. -
Research News: Study: Customizing simple regimen raises adherence
Hospital admissions related to poor medication adherence cost the United States billions of dollars a year. Two physicians recently reviewed the literature and discussed adherence to medication in the Aug. 5 issue of The New England Journal of Medicine. -
News Briefs
The FDA has asked Purdue Pharma LP to withdraw its pain management drug hydromorphone hydrochloride (Palladone) from the market. The agency made this request after acquiring new information about serious and potentially fatal adverse reactions that can occur when hydromorphone extended-release capsules are taken together with alcohol. -
New FDA Approvals
New indication for celecoxib (Celebrex) by Pfizer. The FDA has approved the selective COX-2 inhibitor celecoxib (Celebrex) for a new indication, the relief of the signs and symptoms associated with ankylosing spondylitis. -
Drug Criteria & Outcomes: Drug evaluation: Dexmethylphenidate hydrochloride tablets (Focalin)
Dexmethylphenidate, d-MPH (Focalin) is a new methylphenidate (d,l-MPH; MPH) formulation of the active enantiomer only. A variety of methylphenidate products are available but only dexmethylphenidate is the purified active enantiomer. -
In The Pipeline
Genelabs Technologies has received orphan drug designation for prasterone (Prestara), its investigational drug for lupus.